Form 8-K - Current report:
SEC Accession No. 0001213900-26-062935
Filing Date
2026-05-29
Accepted
2026-05-29 17:10:41
Documents
13
Period of Report
2026-05-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0292691-8k_actinium.htm   iXBRL 8-K 27594
2 PRESS RELEASE DATED MAY 29, 2026 ea029269101ex99-1.htm EX-99.1 15750
3 GRAPHIC ea029269101_ex99-1img1.jpg GRAPHIC 11193
  Complete submission text file 0001213900-26-062935.txt   230949

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE atnm-20260527.xsd EX-101.SCH 3032
5 XBRL LABEL FILE atnm-20260527_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE atnm-20260527_pre.xml EX-101.PRE 22370
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0292691-8k_actinium_htm.xml XML 3219
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 261045939
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)